X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (23) 23
breast neoplasms - drug therapy (22) 22
breast cancer (21) 21
female (21) 21
oncology (19) 19
index medicus (18) 18
middle aged (17) 17
trastuzumab (17) 17
adult (15) 15
breast neoplasms - pathology (15) 15
chemotherapy (13) 13
chemotherapy, adjuvant (13) 13
aged (12) 12
treatment outcome (12) 12
cancer (10) 10
therapy (10) 10
disease-free survival (9) 9
drug therapy (9) 9
hematology, oncology and palliative medicine (9) 9
receptor, erbb-2 - metabolism (9) 9
antineoplastic agents - therapeutic use (8) 8
care and treatment (8) 8
adjuvant chemotherapy (7) 7
antimitotic agents (7) 7
antineoplastic agents (7) 7
breast neoplasms - mortality (7) 7
drug administration schedule (7) 7
adjuvant treatment (6) 6
antineoplastic agents - adverse effects (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
breast neoplasms - genetics (6) 6
breast neoplasms - metabolism (6) 6
cancer therapies (6) 6
efficacy (6) 6
follow-up studies (6) 6
neoplasm staging (6) 6
quinazolines - adverse effects (6) 6
1st-line treatment (5) 5
antibodies, monoclonal - therapeutic use (5) 5
antibodies, monoclonal, humanized (5) 5
antibodies, monoclonal, humanized - administration & dosage (5) 5
antibodies, monoclonal, humanized - adverse effects (5) 5
her2 (5) 5
medicine, general & internal (5) 5
phase-ii (5) 5
product development (5) 5
receptor (5) 5
receptor, erbb-2 - antagonists & inhibitors (5) 5
research (5) 5
safety (5) 5
analysis (4) 4
docetaxel (4) 4
expression (4) 4
internal medicine (4) 4
monoclonal-antibody (4) 4
prognosis (4) 4
radiation therapy (4) 4
receptor, erbb-2 - analysis (4) 4
receptor, erbb-2 - genetics (4) 4
surgery (4) 4
survival analysis (4) 4
trial (4) 4
women (4) 4
abridged index medicus (3) 3
adjuvant (3) 3
aged, 80 and over (3) 3
antibodies, monoclonal - adverse effects (3) 3
antineoplastic agents - administration & dosage (3) 3
biomarkers, tumor - analysis (3) 3
breast neoplasms - surgery (3) 3
cancer patients (3) 3
clinical trials (3) 3
combined modality therapy (3) 3
diseases (3) 3
dose-response relationship, drug (3) 3
epidermal growth factor (3) 3
follow-up (3) 3
genetic aspects (3) 3
heart diseases - chemically induced (3) 3
hematology (3) 3
kaplan-meier estimate (3) 3
lapatinib (3) 3
lymphatic metastasis (3) 3
medicine (3) 3
neoadjuvant therapy (3) 3
paclitaxel (3) 3
patient selection (3) 3
plus (3) 3
proportional hazards models (3) 3
quinazolines - administration & dosage (3) 3
randomized controlled trials as topic (3) 3
recurrence (3) 3
skin and connective tissue diseases (3) 3
survival (3) 3
tumors (3) 3
administration, oral (2) 2
anthracyclines (2) 2
anthracyclines - administration & dosage (2) 2
anthracyclines - adverse effects (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 10, pp. 1137 - 1146
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 1, pp. 88 - 96
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 3, pp. 357 - 366
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10075, pp. 1195 - 1205
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9816, pp. 633 - 640
Summary Background The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and... 
Internal Medicine | ADJUVANT CHEMOTHERAPY | APOPTOSIS | CELLS | WOMEN | MEDICINE, GENERAL & INTERNAL | GW572016 | ERBB2 | INHIBITOR | PLUS | Breast Neoplasms - surgery | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Diarrhea - chemically induced | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Liver - drug effects | Adult | Female | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Biomarkers, Tumor - antagonists & inhibitors | Paclitaxel - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Liver - metabolism | Paclitaxel - adverse effects | Treatment Outcome | Breast Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Neoadjuvant Therapy - methods | Quinazolines - adverse effects | Aged | Infusions, Intravenous | Receptor, ErbB-2 - analysis | Trastuzumab | Drug therapy | Breast cancer | Genetic aspects | Medical research | Ligands | Cytotoxicity | Mammography | Kinases | Cancer therapies | pathology | Liver | methods | Antibodies | Oral | Quinazolines | Breast Neoplasms | Tumor Markers | administration & dosage | Surgery | Paclitaxel | Neoadjuvant Therapy | Adjuvant | Monoclonal | chemistry | Administration | drug therapy | chemically induced | Intravenous | Infusions | Humanized | Antineoplastic Combined Chemotherapy Protocols | Diarrhea | drug effects | Biological | analysis | Kirurgi | antagonists & inhibitors | Chemotherapy | Receptor | adverse effects | metabolism | Cancer and Oncology | therapeutic use | Cancer och onkologi | erbB-2
Journal Article
Lancet, The, ISSN 0140-6736, 2013, Volume 382, Issue 9897, pp. 1021 - 1028
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 3, pp. 236 - 244
Journal Article
Lancet, The, ISSN 0140-6736, 2007, Volume 369, Issue 9555, pp. 29 - 36
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 3, pp. 244 - 248
Journal Article